ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

Clinical Trial ID NCT00709527

Rank	Title	Journal	Year	PubWeight™‹?›
1	Immunology of age-related macular degeneration.	Nat Rev Immunol	2013	2.14
2	Complement in immune and inflammatory disorders: therapeutic interventions.	J Immunol	2013	1.64
3	The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application.	Graefes Arch Clin Exp Ophthalmol	2010	1.12
4	Applying complement therapeutics to rare diseases.	Clin Immunol	2015	0.87
5	Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration.	J Clin Med	2015	0.83
6	Present and possible therapies for age-related macular degeneration.	ISRN Ophthalmol	2014	0.79
7	Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers.	Int J Mol Sci	2016	0.78
8	Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling.	Int J Mol Sci	2013	0.78
9	Targeting the complement system for the management of retinal inflammatory and degenerative diseases.	Eur J Pharmacol	2016	0.78